XLXijian Liu

Xijian Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xijian Liu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Leilei Liu

    Shandong University of Traditional Chinese Medicine, Jinan

    2 shared publications
  • Shuzhi Liang

    Shandong University of Traditional Chinese Medicine, Jinan

    2 shared publications
  • Yan Zhang

    Shandong University of Traditional Chinese Medicine, Jinan

    2 shared publications
  • Bo Wang

    Department of Traditional Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

    1 shared publication
  • Guoxiu Zu

    Shandong University of Traditional Chinese Medicine, Jinan

    1 shared publication
  • Han Xu

    Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China

    1 shared publication

Latest Publications

  • Open Access

    S100a8/A9 proteins: critical regulators of inflammation in cardiovascular diseases

    by Yu Sun, Han Xu, Weihan Gao, Jinlan Deng, Xiayinan Song, Jie Li, Xijian Liu, \R\Nyu Sun

    Neutrophil hyperexpression is recognized as a key prognostic factor for inflammation and is closely related to the emergence of a wide range of cardiovascular disorders. In recent years, S100 calcium binding protein A8/A9 (S100A8/A9) derived from neutrophils has attracted increasing attention as an important warning protein for cardiovascular disease. This article evaluates the utility of S100A8/A9 protein as a biomarker and therapeutic target for diagnosing cardiovascular diseases, considering its structural features, fundamental biological properties, and its multifaceted influence on cardiovascular conditions including atherosclerosis, myocardial infarction, myocardial ischemia/reperfusion injury, and heart failure.


  • Genipin inhibits proliferation of gastric cancer cells by inducing ferroptosis: an integrated study of network pharmacology and bioinformatics study

    by Yalu Mi, Hui Shan, Bo Wang, Huidi Tang, Jihui Jia, Xijian Liu, Qing Yang

    Ferroptosis has been demonstrated to suppress cancer development and is targeted for cancer therapy. Genipin, an iridoid constituent in Gardeniae Fructus, has been reported to exert anti-cancer abilities. However, whether genipin could induce ferroptosis remains unclear. The purpose of this study is to explore the anti-gastric cancer (GC) effects of genipin by inducing ferroptosis and to identify the potential targets. CCK-8 and colony formation assays were performed to evaluate the anti-GC effects of genipin. Flowcytometry and western blot were used to indicate ferroptosis-inducing ability of genipin. The potential targets of genipin were analyzed by network pharmacology, screened using UALCAN and KM-plotter database and evaluated by molecular docking. The results showed that genipin inhibited cell viability and proliferation of GC cells. Genipin treatment decreased levels of GPX4 and SLC7A11, induced accumulation of lipid peroxidation intracellularly and led to ferroptosis in GC cells. Network pharmacology analysis identified that lipid- and ROS-related pathways involved in ferroptosis ranked high among genipin-GC common targets. Data from UALCAN and KM-plotter database demonstrated that expression levels of ferroptosis-related targets, including AURKA, BCAT2, DHODH, and GPI, increased in GC tissues and the higher levels of the above four targets were related to tumor stage, tumor grade, and poor prognosis. Among these four targets, AURKA, BCAT2, and DHODH were confirmed by molecular docking with binding energies less than − 5. Taken together, our study demonstrates that genipin could exert anti-GC ability by inducing ferroptosis and provides evidence for the potential application of genipin in GC treatment.


  • Open Access

    Mechanisms underlying the therapeutic effects of banxiaxiexin decoction in treating vascular dementia based on network pharmacology and molecular docking

    by Shuzhi Liang, Leilei Liu, Guoxiu Zu, Xijian Liu, Yan Zhang

    Background The Banxiaxiexin decoction constitutes a prevalent Traditional Chinese Medicine (TCM) formulation employed for the therapeutic intervention of vascular dementia. Despite its routine clinical application, the underlying molecular mechanisms that mediate its pharmacological efficacy remain elusive. To address this lacuna, the present study employed a multi-pronged analytical approach involving network pharmacology and molecular docking techniques. Methods Active phytochemical constituents and relevant pharmacological targets of Banxiaxiexin decoction were elucidated using data procured from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Targets germane to vascular dementia were aggregated from a comprehensive range of databases, including GeneCards, Online Mendelian Inheritance in Man (OMIM), Drugbank, Pharmacogenomics Knowledge Base (PharmGKB), and Therapeutic Target Database (TTD). A Protein-Protein Interaction (PPI) network was constructed to isolate core targets. Subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were executed using METASCAPE. Tissue and organ-specific distribution of these targets were subsequently assessed. Molecular docking protocols were employed to evaluate the interactions between the identified potential targets and active constituents. Molecular dynamics simulations were conducted to further scrutinize the optimal core protein–compound complexes identified through molecular docking. Results A total of 133 active compounds and 64 putative targets of Banxiaxiexin decoction were identified. Topological analyses of the PPI network revealed a subset of 20 core targets. GO and KEGG pathway enrichment analyses substantiated that Banxiaxiexin decoction modulates genes implicated in pathways associated with oncogenesis, lipid metabolism and atherosclerosis, as well as Alzheimer's disease signaling pathways. Both molecular docking and molecular dynamics simulations affirmed a robust binding affinity between the active compounds and the isolated targets. Conclusions The present study adeptly elucidates the active components, prospective targets, and putative pathways implicated in the therapeutic efficacy of Banxiaxiexin decoction for vascular dementia. The data presented herein offer a novel methodological framework for the future investigation of the molecular mechanisms by which Banxiaxiexin decoction exerts its therapeutic effects. Furthermore, the delineated active constituents may serve as a propitious reservoir for subsequent drug development endeavors targeting vascular dementia.

  • Effects of BXSMD on ESR1 and ESR2 expression in CSD female mice

    by Shujun Wang, Leilei Liu, Shuzhi Liang, Jinni Yang, Yan Zhang, Xijian Liu


  • Open Access

    Molecular targets and mechanisms involved in the action of Banxia Shumi decoction in insomnia treatment

    by Yan Zhang, Zhe Zhang, Shu-Jun Wang, Jin-Ni Yang, Zhong-Mi Zhao, Xi-Jian Liu

    Insomnia is a common sleep-wake rhythm disorder, which is closely associated with the occurrence of many serious diseases. Recent researches suggest that circadian rhythms play an important role in regulating sleep duration and sleep quality. Banxia Shumi decoction (BSXM) is a well-known Chinese formula used to treat insomnia in China. However, the overall molecular mechanism behind this therapeutic effect has not yet been fully elucidated. This study aimed to identify the molecular targets and mechanisms involved in the action of BSXM during the treatment of insomnia. Using network pharmacology and molecular docking methods, we investigated the molecular targets and underlying mechanisms of action of BSXM in insomnia therapy. We identified 8 active compounds from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and the traditional Chinese medicine integrative database that corresponded to 26 target genes involved in insomnia treatment. The compound-differentially expressed genes of the BXSM network indicated that cavidine and gondoic acid could potentially become key components of drugs used for insomnia treatment. Further analysis revealed that GSK3B, MAPK14, IGF1R, CCL5, and BCL2L11 were core targets significantly associated with the circadian clock. Pathway enrichment analysis of Kyoto Encyclopedia of Genes and Genomes revealed that epidermal growth factor receptor tyrosine kinase inhibitor resistance was the most prominently enriched pathway for BSXM in the insomnia treatment. The forkhead box O signaling pathway was also found to be significantly enriched. These targets were validated using the Gene Expression Omnibus dataset. Molecular docking studies were performed to confirm the binding of cavidine and gondoic acid to the identified core targets. To our knowledge, our study confirmed for the first time that the multi-component, multi-target, and multi-pathway characteristics of BXSM may be the potential mechanism for treating insomnia with respect to the circadian clock gene. The results of this study provided theoretical guidance for researchers to further explore its mechanism of action.